How Dublin Keeps Big Pharma Happy
How Dublin Keeps Big Pharma Happy
“It’s moving from basic manufacturing to sophisticated R&D to fend off rivals”
The Trials of ImClone
The Trials of ImClone
“A founder in handcuffs, financials in disarray, and a vital product in doubt-for CEO Daniel Lynch, it was the turnaround from hell.”
The Time Is Right for These Seven Biotechs
The Time Is Right for These Seven Biotechs
“In most years, biotechs decline in the spring as investors anticipate a summer hiatus in the conferences where new clinical results are announced. They rally in the fall as the conference schedule and the volume of news increases … Buy when the playing field is biased in my favor, and avoid it when it isn’t. “
12
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments